Dapagliflozin 10 mg + Metformin 500 mg (ER) Tablets – DAPILA M 10/500

Dapagliflozin 10 mg + Metformin 500 mg (ER) Tablets – Targeted Glycemic Management with Cardiometabolic Benefits.

DAPILA M 10/500: The Dual combination of Dapagliflozin 10 mg + Metformin HCl 500 mg is a combination that has Dapagliflozin, a SGLT 2 sodium-glucose co-transporter-2 inhibitor, and Metformin, a biguanide derivative. Dapagliflozin helps to manage cardiovascular-associated type 2 diabetes by inhibiting glucose reabsorption in the kidneys’ proximal convoluted tubules (PCT). This action increases glucose excretion through urination. Metformin reduces glucose production in the liver (hepatic gluconeogenesis), increases glycolysis, enhances peripheral glucose uptake, and improves cellular insulin sensitivity.

Recommended BY SPECIALISTS:
Diabetologists: It is mainly used to recommend the specialists for the treatment of Type 2 diabetes, especially in overweight, insulin-resistant, or cardiometabolic risk patients
General Physicians: It is mainly used to prefer this combination for the treatment as a first-line or second-line therapy in patients with inadequate control on Metformin alone
Cardiologists: It is mainly used to prefer this combination of diabetic patients with heart failure (especially HFrEF) or high cardiovascular risk

Key Benefits of Dapagliflozin 10 mg + Metformin 500 mg (ER) Tablets – DAPILA M 10/500
Dual anti-diabetic agent: *It provides synergistic action with two different mechanisms, as diabetes enhances glucose excretion by urination, and Metformin improves insulin sensitivity.
Dapagliflozin provides cardioprotective action: To make this combination suitable for diabetic patients at high risk of cardiovascular disease.
Both agents in combination: It has a lower risk of hypoglycemia and improves insulin sensitivity with a convenient dosage

INDICATIONS:
Type-2 Diabetes
Type-2 Diabetes with CVD
Weight management
Type 2 diabetes with CKD